- Home
- CRWD vs SNY Comparison
CRWD vs SNY Comparison
Compare CRWD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWD
- SNY
- Stock Information
- Founded
- CRWD 2011
- SNY 1994
- Country
- CRWD United States
- SNY France
- Employees
- CRWD N/A
- SNY N/A
- Industry
- CRWD EDP Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- CRWD Technology
- SNY Health Care
- Exchange
- CRWD Nasdaq
- SNY Nasdaq
- Market Cap
- CRWD 122.6B
- SNY 116.5B
- IPO Year
- CRWD 2019
- SNY N/A
- Fundamental
- Price
- CRWD $507.38
- SNY $48.12
- Analyst Decision
- CRWD Buy
- SNY Buy
- Analyst Count
- CRWD 47
- SNY 2
- Target Price
- CRWD $451.68
- SNY $62.50
- AVG Volume (30 Days)
- CRWD 4.2M
- SNY 2.1M
- Earning Date
- CRWD 06-03-2025
- SNY 07-24-2025
- Dividend Yield
- CRWD N/A
- SNY 3.31%
- EPS Growth
- CRWD N/A
- SNY 39.56
- EPS
- CRWD N/A
- SNY 5.45
- Revenue
- CRWD $4,136,022,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- CRWD $23.38
- SNY $3.39
- Revenue Next Year
- CRWD $21.77
- SNY $7.05
- P/E Ratio
- CRWD N/A
- SNY $8.86
- Revenue Growth
- CRWD 25.94
- SNY N/A
- 52 Week Low
- CRWD $200.81
- SNY $45.80
- 52 Week High
- CRWD $510.02
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- CRWD 65.55
- SNY 41.60
- Support Level
- CRWD $461.51
- SNY $47.56
- Resistance Level
- CRWD $494.30
- SNY $48.93
- Average True Range (ATR)
- CRWD 15.11
- SNY 0.64
- MACD
- CRWD 0.24
- SNY -0.06
- Stochastic Oscillator
- CRWD 97.70
- SNY 26.24
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.